Home > IP News
Impax and J&J settle Concerta patent lawsuits
Impax says its generic version of Concerta will go on sale in July 2013 in settlement with J&J
NEW YORK (AP) -- Impax Laboratories Inc. said Friday its generic version of the attention deficit hyperactivity drug Concerta should go on sale in July after the company settled lawsuits with drugmaker Johnson & Johnson.
Impax and Teva Pharmaceutical Industries Ltd. received a license to start selling their generic on July 14, 2013. Impax said U.S. sales of Concerta totaled $1.2 billion over the 12-month period ending in July. That includes the brand-name version and an authorized generic made by Watson Pharmaceuticals Inc.